Clinical classification of pulmonary hypertension.

Pulmonary hypertension is a prevalent disease of multiple etiologies. Over the years, different attempts at nomenclature and classification, largely based on morphologic findings at autopsy, have met with limited success. Recent advances in medical and surgical treatment, and the promise of effective approaches to prevention, have prompted the development of a clinical classification designed to take advantage of the new promising interventions. This article traces the growth of understanding of the pulmonary hypertensive diseases that has enabled the development of a clinical classification oriented towards prevention and treatment.

[1]  M. Humbert,et al.  High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. , 1998, AJR. American journal of roentgenology.

[2]  S. Hodge,et al.  BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.

[3]  R. Barst,et al.  Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. , 2002, The Journal of rheumatology.

[4]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[5]  D. Schraufnagel,et al.  Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease. , 1996, The European respiratory journal.

[6]  M. Humbert,et al.  Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. , 2002, Radiology.

[7]  J. Edwards,et al.  The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.

[8]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[9]  E. Braunwald,et al.  FAMILIAL PULMONARY HYPERTENSION. , 1963, The New England journal of medicine.

[10]  R. Escamilla,et al.  Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. , 1995, The European respiratory journal.

[11]  R. Abbate,et al.  Pulmonary hypertension associated with long-standing thrombocytosis. , 1991, Chest.

[12]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[13]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[14]  R. Barst,et al.  Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. , 1992, The American review of respiratory disease.

[15]  K. Peterson,et al.  Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism. , 1987, The Journal of thoracic and cardiovascular surgery.

[16]  E. Shinebourne,et al.  Effect of long term oxygen treatment at home in children with pulmonary vascular disease. , 1986, British heart journal.

[17]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[18]  J. Mandel,et al.  Pulmonary veno-occlusive disease. , 2000, American journal of respiratory and critical care medicine.

[19]  Wagenvoort Ca.  The pathology of primary pulmonary hypertension. , 1970 .

[20]  M. Humbert,et al.  Severe pulmonary hypertension in histiocytosis X. , 2000, American journal of respiratory and critical care medicine.

[21]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[22]  M. Humbert,et al.  Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis , 2002, European Respiratory Journal.

[23]  M. Gladwin,et al.  Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. , 2003, American journal of respiratory and critical care medicine.

[24]  P. Dartevelle,et al.  [Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]. , 1994, Archives des maladies du coeur et des vaisseaux.

[25]  M. Gladwin,et al.  Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. , 2001, American journal of respiratory and critical care medicine.

[26]  D. Dresdale,et al.  Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.

[27]  A. Fishman.  Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[28]  P. Dartevelle,et al.  Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  A. Fishman.  Dietary Pulmonary Hypertension , 1974, Circulation research.

[30]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[31]  W. Auger,et al.  Chronic major-vessel thromboembolic pulmonary hypertension. , 1990, Circulation.

[32]  J. R. Kuipers,et al.  Familial pulmonary veno-occlusive disease: a case report. , 1977, Thorax.

[33]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[34]  M. Humbert,et al.  Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study , 1999 .

[35]  R. Sapru,et al.  Pulmonary hypertension in patients with pulmonary arteriovenous fistulae. , 1969, British heart journal.

[36]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[37]  P. Thistlethwaite,et al.  Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. , 2003, The Annals of thoracic surgery.

[38]  E. Beutler,et al.  Pulmonary Hypertension Developing after Alglucerase Therapy in Two Patients with Type 1 Gaucher Disease Complicated by the Hepatopulmonary Syndrome , 1996, Annals of Internal Medicine.

[39]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[40]  N. Voelkel,et al.  Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. , 1999, The Journal of clinical investigation.

[41]  T. Takemura,et al.  Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. , 1992, Human pathology.

[42]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.

[43]  P. Dartevelle,et al.  Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. , 1995, Chest.

[44]  E. Ruchelli,et al.  Pulmonary veno-occlusive disease. Another vascular disorder associated with human immunodeficiency virus infection? , 1994, Archives of pathology & laboratory medicine.

[45]  C. Pizzo,et al.  Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. , 1980, Pediatrics.

[46]  P. Wood.  The Eisenmenger Syndrome , 1958 .

[47]  L. Ackerson,et al.  Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. , 1996, American journal of respiratory and critical care medicine.

[48]  E. Weitzenblum,et al.  Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. , 2015, The American review of respiratory disease.

[49]  Yuan-Tsong Chen,et al.  Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. , 1995, American journal of human genetics.

[50]  John Arul Phillips,et al.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.

[51]  M. Humbert,et al.  Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[52]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.

[53]  F. Basset,et al.  Chronic cor pulmonale in pulmonary sarcoidosis. , 1978, Thorax.

[54]  P. Presbitero,et al.  Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[55]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[56]  M. Humbert,et al.  Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.

[57]  H. Winer-Muram,et al.  Pulmonary capillary hemangiomatosis: a clinicopathologic review. , 1994, The Annals of thoracic surgery.

[58]  G. Garcia-Manero,et al.  Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases , 1999, American journal of hematology.

[59]  S. Chuncharunee,et al.  Pulmonary Arterial Hypertension in Previously Splenectomized Patients with β-Thalassemic Disorders , 2003 .

[60]  J. Morse.  Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension. , 2002, Chest.

[61]  T. De,et al.  Parenteral nutrition before gastrointestinal surgery. , 1982 .

[62]  H. Ichinose,et al.  Pulmonary veno-occlusive disease: Report of a case with pseudoangiomatous features , 1977 .

[63]  R. Spellberg,et al.  Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. , 1993, Chest.

[64]  J. Rouleau,et al.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[65]  M. Humbert,et al.  Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). , 1998, Chest.

[66]  D L Buschman,et al.  Pulmonary histiocytosis X: comparison of radiographic and CT findings. , 1989, Radiology.

[67]  R. R. Wolfe,et al.  Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.

[68]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[69]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[70]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease. , 1994, The American journal of cardiology.

[71]  A. Oberg,et al.  Unexplained pulmonary hypertension in chronic myeloproliferative disorders. , 2001, Chest.

[72]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[73]  E. Trell,et al.  Familial pulmonary hypertension and multiple abnormalities of large systemic arteries in Osler's disease. , 1972, The American journal of medicine.

[74]  K. Peterson,et al.  Pulmonary vascular occlusion and fibrosing mediastinitis. , 1986, Chest.

[75]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[76]  J. Spijker,et al.  Capillary haemangiomatosis of the lungs , 1978, Histopathology.

[77]  M. Keszler,et al.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.

[78]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[79]  J. Newman,et al.  Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.

[80]  S. Schneeweiss,et al.  Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. , 2000, Chest.